StockNews.AI
MGRM
StockNews.AI
160 days

Monogram Technologies Reports Full Year 2024 Financial Results

1. MGRM submitted its formal response to the FDA's AIR, moving forward in regulatory process. 2. A business update call is scheduled for March 12, 2025, highlighting operational results.

Earnings
-0.43%Current Return
VS
-1.32%S&P 500
$2.3203/12 04:05 PM EDTEvent Start
$2.3103/13 10:39 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Completion of testing and FDA response typically signal positive regulatory progress, enhancing investor confidence. Historical parallels include companies like Intuitive Surgical seeing stock gains post-regulatory milestones.

How important is it?

The FDA's engagement reflects confidence in MGRM's product pipeline, likely influencing stock performance positively. This marks a critical milestone for future commercial prospects.

Why Short Term?

The upcoming business update could lead to immediate market reactions based on disclosed results and insights. Recent comparable events in biotech have shown immediate impacts on stock prices.

Related Companies

ISRGMDTSTRY
Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.

Related News